Quantcast

Fixed-Dose Combination Drugs for Leading Diseases Report Provides a Discussion of the History and Advantages of Fixed-Dose Combination Drug Products

May 20, 2008

Research and Markets (http://www.researchandmarkets.com/reports/c92368) has announced the addition of “The Global Market for Fixed-Dose Combination Drugs for Leading Diseases” to their offering.

“The Global Market for Fixed-Dose Combination Drugs for Leading Diseases” analyzes products and applications of fixed-dose combination drugs utilized in the treatment of cardiovascular diseases (hypercholesterolemia and hypertension), diabetes, infectious diseases (bacterial infections, Helicobacter pylori, acquired immune deficiency syndrome–AIDS, HIV infection and tuberculosis), psychiatric disorders (depression and Alzheimer’s disease) and respiratory diseases (asthma and chronic obstructive pulmonary disease–COPD). Not included in this report are combination products used as oral contraceptives, combinations of a drug (such as a monoclonal antibody) and a radioactive component, or combination vaccine products. Also not included are over-the-counter (OTC) and prescription non-systemic fixed-dose combination products.

The scope of this report is worldwide. The Overview section provides a discussion of the history and advantages of fixed-dose combination drug products. Described are the leading diseases for which fixed-dose combination products are available or are projected to be introduced during the forecast period. This section also discusses the various types of products available or in development within the categories included in this report.

The Products and Applications section provides a synopsis of more than 70 fixed-dose combination drug products, including those currently marketed and those in Phase II or later development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, when possible, as well as worldwide market size and growth estimates for fixed-dose combination drug categories as a whole.

Contents:

Introduction 1

Objectives And Goals Of Study 1

Contribution Of The Study And For Whom 1

Study Scope And Format 1

Methodology 2

Information Sources 2

Other Market Research Reports Recently Published By The Author 3

Executive Summary 4

Overview 6

Definition Of A Combination Drug 6

Advantages Of Fixed-Dose Combination Drugs 6

Potentiation And Cancellation 7

Decreased Dosing Means Better Compliance And Lower Administrative Costs 7

Combination Drugs Targeting Infectious Agents Rather Than Body Tissues 8

The Disadvantages Of Fixed-Dose Combination Drugs 9

Regulations Relating To Fixed-Dose Combination Drugs 10

Incentives And Barriers To The Development Of Fixed-Dose Combination Drugs 11

Market-Related Advantages Of Fixed-Dose

Combination Drugs 11

The Challenges Of Manufacturing Fixed-Dose Combination Drugs 11

Legal/Intellectual Property Issues Relating To Fixed-Dose Combination Products 13

Products And Applications 15

Cardiovascular Diseases 15

Infectious Diseases 17

Psychiatric Diseases 19

Cardiovascular Diseases 20

Hypertension 21

Hypercholesterolemia 32

Diabetes 41

Fixed-Dose Combination Drugs For Diabetes Introduced 42

Three New Fixed-Dose Combination Products Introduced In 2005 And 2006 43

The Market For Fixed-Dose Combination Drugs To Treat Diabetes 44

Fixed-Dose Combination Drugs In Development 44

Infectious Diseases 45

Leading Fixed-Dose Combination Antibiotic Drugs 46

The Market For Fixed-Dose Combination Drugs To Treat Bacterial Infections 48

Helicobacter Pylori Infection 48

Human Immunodeficiency Virus (Hiv) And Acquired Immune Deficiency Syndrome (Aids) 51

Tuberculosis 69

Psychiatric Disorders 74

Depression 74

The Market For Fixed-Dose Combination Products To Treat Psychiatric Disorders 76

Fixed-Dose Combination Products In Phase Ii Or Later Development For The Treatment Of

Psychiatric Disorders 76

Fixed-Dose Combination Products For The Treatment Of Alzheimer’s Disease 78

Respiratory Diseases 80

Asthma 80

Chronic Obstructive Pulmonary Disease (Copd) 81

Currently Marketed Products For The Treatment Of Asthma

The Market For Drugs To Treat Asthma And Copd 89

Fixed-Dose Combination Products In Phase Ii Or Later Development To Treat Asthma And Copd 93

Vr315 95

Industry 96

The Number Of Blockbuster Drugs On The Worldwide Pharmaceutical Market Approaches 100 96

U.S. Pharmaceutical Industry Growth Expected To Increase Slightly 97

More Mergers, Acquisitions And Licensing 97

Potential Fixed-Dose Combination Drugs Lead The Market 98

Leading Manufacturers In The Fixed-Dose Combination

Drug Market 98

Company Profiles 99

List Of Tables

List Of Figures

Summary Figures

For more information visit http://www.researchandmarkets.com/reports/c92368




comments powered by Disqus